V. Craig Jordan

V. Craig Jordan
CMG OBE
V. Craig Jordan
Born(1947-07-25)July 25, 1947
New Braunfels, Texas, U.S.
DiedJune 9, 2024(2024-06-09) (aged 76)
Houston, Texas, U.S.
Alma materUniversity of Leeds
Known for"Father of Tamoxifen"; Research on SERMs, particularly tamoxifen and raloxifene
Awards
Scientific career
FieldsPharmacology, Cancer Research
InstitutionsUniversity of Texas MD Anderson Cancer Center; University of Leeds; Ludwig Institute, Bern, Switzerland; University of Wisconsin–Madison; Northwestern University; Fox Chase Cancer Center; Georgetown University

Virgil Craig Jordan, CMG, OBE, FMedSci, (July 25, 1947 – June 9, 2024) was an American and British scientist specializing in drugs for breast cancer treatment and prevention.[1] He was Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones.[2] His later work branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). He later worked on developing a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer.[3]

Jordan's paper The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results from the More Randomized Trial[4] was one of the top 20 most cited papers in breast cancer research during 2003 and 2004.[5]

  1. ^ Gupta, S. (2011). "Profile of V. Craig Jordan". Proceedings of the National Academy of Sciences. 108 (47): 18876–8. Bibcode:2011PNAS..10818876G. doi:10.1073/pnas.1117698108. PMC 3223455. PMID 22089238.
  2. ^ Jordan, V. C. (2008). "Tamoxifen: Catalyst for the change to targeted therapy". European Journal of Cancer. 44 (1): 30–38. doi:10.1016/j.ejca.2007.11.002. PMC 2566958. PMID 18068350.
  3. ^ Sweeney, E. E.; Fan, P; Jordan, V. C. (2014). "Molecular modulation of estrogen-induced apoptosis by synthetic progestins in hormone replacement therapy: An insight into the women's health initiative study". Cancer Research. 74 (23): 7060–8. doi:10.1158/0008-5472.CAN-14-1784. PMC 4254051. PMID 25304262.
  4. ^ Cummings, S. R.; Eckert, S.; Krueger, K. A.; Grady, D.; Powles, T. J.; Cauley, J. A.; Norton, L.; Nickelsen, T.; Bjarnason, N. H.; Morrow, M.; Lippman, M. E.; Black, D.; Glusman, J. E.; Costa, A.; Jordan, V. C. (1999). "The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation". JAMA: The Journal of the American Medical Association. 281 (23): 2189–2197. doi:10.1001/jama.281.23.2189. PMID 10376571.
  5. ^ Essential Science Indicators - Special Topics, Breast Cancer, Top 20 Papers in last two year period.[1] Retrieved August 22, 2006.